$25.89—Stale · unknown old
NASDAQ • Last print unknown ago
$25.89—Stale · unknown old
The Direxion Daily LLY Bull 2X ETF (ELIL) is designed to provide 2x the daily performance of the LLY stock, primarily focusing on Eli Lilly and Company, a leader in the biopharmaceutical sector. The ETF's performance is driven by Eli Lilly's strong pipeline of innovative drugs, particularly in diabetes and oncology, which are expected to generate significant revenue growth.
The ETF generates returns by leveraging its investment in Eli Lilly, aiming to amplify daily price movements. This structure allows investors to gain enhanced exposure to the underlying stock's volatility, appealing to those seeking short-term trading opportunities.
Eli Lilly's drug approval announcements, particularly in diabetes and oncology
Market sentiment towards biotech sector performance
Changes in healthcare regulations impacting drug pricing
Overall market volatility affecting leveraged ETFs
Regulatory changes affecting drug pricing and approval processes
Technological disruptions in drug development
Emerging competition from generic drugs and biosimilars
Innovative therapies from rival biotech firms
Potential volatility in Eli Lilly's stock price affecting ETF performance
Liquidity risks associated with leveraged ETFs during market downturns
moderate - the performance of the ETF is somewhat linked to overall economic conditions, as healthcare spending can fluctuate with economic cycles.
Higher interest rates can lead to increased borrowing costs for biotech firms, potentially impacting their valuations and stock performance, thereby affecting the ETF.
minimal - the ETF does not have significant credit exposure as it primarily tracks the performance of Eli Lilly.
momentum - the ETF appeals to investors looking for short-term gains through leveraged exposure to Eli Lilly's stock movements.
high - the ETF is expected to exhibit high volatility due to its leveraged nature.